← All trials
NCT04035785
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 28, 2019
- Primary completion
- Jul 28, 2019
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- China Academy of Chinese Medical SciencesOverall official - principal investigator
- China Academy of Chinese Medical SciencesCollaborator
- Shanghai UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- China Academy of Chinese Medical SciencesReponsible party - principal investigator
- Capital Medical UniversityCollaborator
- Chengdu University of Traditional Chinese MedicinesCollaborator
- Peking UniversityCollaborator
- Shenzhen maternal and child health care hospitalCollaborator
- Tianjin University of Traditional Chinese MedicineCollaborator
- Heilongjiang University of Traditional Chinese MedicineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.